缺血性心脏病：管理的代谢方法
Ischemic heart disease: metabolic approaches to management.
作者信息
Pauly Daniel F, Pepine Carl J
机构信息
University of Florida College of Medicine, Division of Cardiovascular Medicine, Gainesville, Florida 32610, USA.
出版信息
Clin Cardiol. 2004 Aug;27(8):439-41. doi: 10.1002/clc.4960270802.
Abstract
The number of patients with coronary artery disease and its risk factors is increasing in Western nations. New treatments for these patients may soon include a class of agents known as the metabolic modulators. This group of agents consists of the partial fatty acid oxidation inhibitors trimetazidine and ranolazine, as well as dichloroacetate, which promotes carbohydrate utilization. Metabolic modulators also include the nutriceuticals L-carnitine and D-ribose. The available evidence regarding the benefits of each of these five agents is reviewed.
摘要
在西方国家，患有冠状动脉疾病及其风险因素的患者数量正在增加。针对这些患者的新治疗方法可能很快会包括一类被称为代谢调节剂的药物。这类药物包括部分脂肪酸氧化抑制剂曲美他嗪和雷诺嗪，以及促进碳水化合物利用的二氯乙酸。代谢调节剂还包括营养保健品L-肉碱和D-核糖。本文综述了关于这五种药物各自益处的现有证据。
相似文献
1
Ischemic heart disease: metabolic approaches to management.
Clin Cardiol. 2004 Aug;27(8):439-41. doi: 10.1002/clc.4960270802.
2
Role of metabolically active drugs in the management of ischemic heart disease.
Am J Cardiovasc Drugs. 2001;1(1):23-35. doi: 10.2165/00129784-200101010-00003.
3
Metabolic modulators for chronic cardiac ischemia.
J Cardiovasc Pharmacol Ther. 2005 Dec;10(4):217-23. doi: 10.1177/107424840501000402.
4
The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.
Curr Pharm Des. 2009;15(8):841-9. doi: 10.2174/138161209787582075.
5
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Herz. 2002 Nov;27(7):621-36. doi: 10.1007/s00059-002-2428-x.
6
Metabolic management of ischaemic heart disease.
Eur Heart J. 1993 Nov;14 Suppl G:2-5. doi: 10.1093/eurheartj/14.suppl_g.2.
7
Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
Cardiologia. 1995 Oct;40(10):717-20.
8
Metabolic support for the heart: complementary therapy for heart failure?
Eur J Heart Fail. 2016 Dec;18(12):1420-1429. doi: 10.1002/ejhf.678. Epub 2016 Nov 4.
9
Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Eur Heart J. 2004 Apr;25(8):634-41. doi: 10.1016/j.ehj.2004.02.018.
10
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
Circ Res. 2003 Aug 8;93(3):e26-32. doi: 10.1161/01.RES.0000086943.72932.71. Epub 2003 Jul 17.
引用本文的文献
1
Energy metabolism in cardiovascular diseases: unlocking the hidden powerhouse of cardiac pathophysiology.
Front Endocrinol (Lausanne). 2025 Jun 5;16:1617305. doi: 10.3389/fendo.2025.1617305. eCollection 2025.
2
Targeting Cardiac Metabolic Pathways: A Role in Ischemic Management.
Vasc Health Risk Manag. 2020 Sep 14;16:353-365. doi: 10.2147/VHRM.S264130. eCollection 2020.
3
Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.
Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):205-15. doi: 10.1007/s00210-012-0826-z. Epub 2012 Dec 22.
本文引用的文献
1
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
J Am Coll Cardiol. 2004 Apr 21;43(8):1375-82. doi: 10.1016/j.jacc.2003.11.045.
2
Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
JAMA. 2004 Jan 21;291(3):309-16. doi: 10.1001/jama.291.3.309.
3
Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials.
Coron Artery Dis. 2003 Apr;14(2):171-9. doi: 10.1097/00019501-200304000-00010.
4
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Herz. 2002 Nov;27(7):621-36. doi: 10.1007/s00059-002-2428-x.
5
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure.
Eur J Heart Fail. 2002 Jan;4(1):111-6. doi: 10.1016/s1388-9842(01)00240-9.
6
7
Regulation of carbohydrate metabolism in ischemia and reperfusion.
Am Heart J. 2000 Feb;139(2 Pt 3):S115-9. doi: 10.1067/mhj.2000.103919.
8
Ranolazine: a novel metabolic modulator for the treatment of angina.
Gen Pharmacol. 1998 May;30(5):639-45. doi: 10.1016/s0306-3623(97)00301-7.
9
Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes.
Trends Pharmacol Sci. 1993 Oct;14(10):355-60. doi: 10.1016/0165-6147(93)90093-y.
10
Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.
Br J Clin Pharmacol. 1994 Mar;37(3):279-88. doi: 10.1111/j.1365-2125.1994.tb04276.x.
Zotero 插件